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Dear Sophie,
The news in your letter did not come as a great surprise to me because I knew that, sooner or later, you would not be
satisfied with working for Mangledprose Publications. Working on a journal also poses many problems, especially as even
science is now succumbing to the postmodernist idea that everything is a matter of interpretation and that there is no
single correct truth, but many, depending on readers’ point of view, and perhaps also on where the writer works. Now it
would be a happy state if this was earnestly practised, but the paradox is that this politically correct view is accompanied
by the firm belief that the journal knows what’s best for its readers. I cannot understand this view, which assumes that
readers lack critical faculties and need the generous guidance of editors and referees.
What did surprise me in your letter was that, in going back to the bench, you had decided to join a biotech company
rather than returning to the academic path. You should realise that these are prize postmodernist institutions, where
appearance and reality have become intertwined. As I have never heard of Pharmacophormatics I assume that it is newly
formed. It also sounds as if it follows the current fashion of providing an integrative view of the mass of data coming from
the large number of genomic, and now proteomic projects, suitably annotated for use by pharmaceutical companies.
Actually, when you come to think about it, these are the journals or, rather, the textbooks of the future. You see, Sophie,
you have probably not made such a big leap. 
As you will soon discover, a biotech company is formed for one purpose, which is to turn an idea into a concept. A
concept can be sold, especially if there is a little science to support it. I have always believed that we should be working
on resurrection, because it does not take much market research to see that this would have immense public appeal.
Personally, I would love to come back in, say, 100 years, just to find out what later generations have made of the world.
For the success of Lazarus Technologies, we would need some experiments that show resurrection is feasible — a proof
of principle, as it is called. If one could resurrect a mouse for even as little as a picosecond that would suffice.
Everybody knows that all that is needed to extend this into the microsecond range is a little more work and then it is
only a matter of time before we have it working for minutes, days and even months. Here is a multitrillion dollar
industry in the making. 
And here is another. I noticed in the newspaper the other day that the wonder drug of our times, Viagra, has 
been associated with an increased death rate of elderly gentlemen from overexertion. It is clear that we may need 
an antidote and if I had the time and the money, I would be making it. It would be called Niagara. Is
Pharmacophormatics interested?
Companies need a business plan in addition to their programme of research. I have seen many of these texts and
have been tempted to send them for chemical analysis to discover what dope had been smoked by the authors. A
business plan aims mainly at self-consistency; that is, the figures produced need to match the deconstruction
expectations of the investors. Accord with reality is not really necessary, although possibly an advantage.
In true postmodernist style there are, today, three views of biotechnology: the view of Wall Street, the view of big
Pharma, and then, of course, there is the truth. The initial investors are interested only in the story of the company; they
need to convince a few other investors that they could build it into a company of large value and sell it to someone else,
making a quick and profitable exit. I trust your company is going to do something simple, such as provide a useful
service, and not claim to become a vertically integrated pharmaceutical company; most of the ones with this ambition
have ended up as horizontally disintegrated companies.
You will be offered stock options as an incentive to work for the success of the company. Take them. I have spent
years trying to find a way of providing an equivalent incentive for academic labs but have been frustrated by not being
able to discover a financial structure for the scheme. The closest I have come to it is to have the head of the lab share his
Nobel Prize proceeds with the stockholders in the lab. I can also see how this could be turned into futures.
I fear I have been too severe on this industry but, actually, you will find it most exhilarating to join a company right at
its very beginning. It is like going to a new land and moving into a house with the painters and plasterers still busy and
with the furniture undelivered. At the beginning, you will have a free and informal style of life. Enjoy it while it lasts.
The fun disappears when the company acquires a marketing department.
Your ever-loving Grandpa Syd
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